Therapeutic uses of dunaliella powder

• US 20080019997A1
• Filed: 07/10/2007
• Published: 01/24/2008
• Est. Priority Date: 09/24/2003
• Status: Active Grant

• Current Assignee: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Original Assignee: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Inventors: Shaish, Aviv, Harats, Dror
• Granted Patent: US 7,763,255 B2
• Time in Patent Office: Days
• US Class Current: 424/195.17
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 36/05 Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.

Claims

1-18. -18. (canceled)

19. A method for treating atherosclerosis comprising administrating to a subject an effective amount of dried Dunaliella algae, thereby treating the atherosclerosis.

22. The method according to claim 19 wherein said crude Dunaliella powder is administered together with one or more activators of nuclear receptors.

23. The method according to claim 22 wherein the activators of nuclear receptors are peroxisome proliferator-activated receptor α

or γ

(PPARα

or PPARγ

) agonists.

24. The method according to claim 23 wherein the PPARα

or PPARγ

agonists are selected from fibrates and thiazolidinediones.

25. The method according to claim 24 wherein the fibrates are selected from clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and gemfibrozil.

26. The method according to claim 24 wherein the thiazolidinediones are selected from avandia, troglitazone, BRL 49653, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone and rosiglitazone.

27. The method according to claim 19 wherein said crude Dunaliella powder is administered orally.

28. The method according to claim 19 wherein said algae is Dunaliella bardawil.

29. The method according to claim 19, wherein said powder is encapsulated.

20. A method for increasing HDL cholesterol levels in the plasma of a subject having a low HDL cholesterol level, comprising administrating to the subject an effective amount of dried Dunaliella algae, thereby increasing the HDL cholesterol level in a statistically significant manner.

30. The method according to claim 20 wherein said crude Dunaliella powder is administered together with one or more activators of nuclear receptors.

31. The method according to claim 30 wherein the activators of nuclear receptors are peroxisome proliferator-activated receptor α

or γ

(PPARα

or PPARγ

) agonists.

32. The method according to claim 31 wherein the PPARα

or PPARγ

agonists are selected from fibrates and thiazolidinediones.

33. The method according to claim 32 wherein the fibrates are selected from clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and gemfibrozil.

34. The method according to claim 32 wherein the thiazolidinediones are selected from avandia, troglitazone, BRL 49653, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone and rosiglitazone.

35. The method according to claim 20 wherein said crude Dunaliella powder is administered orally.

36. The method according to claim 20 wherein said algae is Dunaliella bardawil.

37. The method according to claim 20 wherein said powder is encapsulated.

21. A method for reducing the size of an atherosclerotic plaque or lesion at the aortic sinus of a subject afflicted with atherosclerosis, comprising administrating to a subject an effective amount of dried Dunaliella algae together with one or more activators of nuclear receptors, thereby reducing the size of the atherosclerotic plaque or lesion.

38. The method according to claim 21 wherein the activators of nuclear receptors are peroxisome proliferator-activated receptor α

or γ

(PPARα

or PPARγ

) agonists.

39. The method according to claim 38 wherein the PPARα

or PPARγ

agonists are selected from fibrates and thiazolidinediones.

40. The method according to claim 39 wherein the fibrates are selected from clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and gemfibrozil.

41. The method according to claim 39 wherein the thiazolidinediones are selected from avandia, troglitazone, BRL 49653, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone and rosiglitazone.

42. The method according to claim 21 wherein said crude Dunaliella powder is administered orally.

43. The method according to claim 21 wherein said algae is Dunaliella bardawil.

44. The method according to claim 21 wherein said powder is encapsulated.